Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
preclamol
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
Preclamol is the (-)enantiomer of 3-PPP (3-(3-hydroxyphenyl)-N-n-propylpiperidine), a **small molecule dopamine receptor partial agonist**. It acts primarily as a mixed agonist-antagonist at dopamine D2 and D3 receptors, showing preferential activity at dopamine autoreceptors and postsynaptic dopamine receptors, with a weaker activity at D1 receptors. Originally investigated for the treatment of **Parkinson's disease** and **schizophrenia**—as an antiparkinsonian and antipsychotic agent—preclamol showed some efficacy in alleviating parkinsonian symptoms and had a mild antipsychotic effect in early studies, but development was discontinued. The drug was initially developed by AstraZeneca.
- Other names
- 3-(3-hydroxyphenyl)-N-n-propylpiperidine
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD1 (Dopamine D1 Receptor)
Beyond the preview
Go deeper on preclamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on preclamol.